Studies have shown that STAT3 and Keap1 are key targets for the treatment of IBD, so we used as targets for molecular docking (Lu et al., 2016; Kasembeli et al., 2018) (Supplementary Table S2). The gene discussed is KEAP1; the disease is inflammatory bowel disease.